Bfsg LLC increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 78.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,624 shares of the specialty pharmaceutical company's stock after acquiring an additional 4,685 shares during the period. Bfsg LLC's holdings in Jazz Pharmaceuticals were worth $2,460,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of JAZZ. Bank of New York Mellon Corp grew its stake in Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company's stock valued at $317,485,000 after acquiring an additional 517,514 shares during the period. Tri Locum Partners LP acquired a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth about $29,995,000. Bank of America Corp DE raised its position in shares of Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company's stock worth $191,848,000 after purchasing an additional 99,656 shares during the last quarter. Amundi raised its position in shares of Jazz Pharmaceuticals by 2,445.3% during the 1st quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company's stock worth $10,519,000 after purchasing an additional 53,454 shares during the last quarter. Finally, Rokos Capital Management LLP purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at about $9,833,000. Hedge funds and other institutional investors own 89.14% of the company's stock.
Insider Activity at Jazz Pharmaceuticals
In other Jazz Pharmaceuticals news, EVP Neena Patil sold 1,200 shares of the company's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the transaction, the executive vice president owned 47,671 shares of the company's stock, valued at $11,485,850.74. This represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total transaction of $472,800.00. Following the transaction, the chief executive officer directly owned 141,394 shares of the company's stock, valued at $33,425,541.60. The trade was a 1.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 101,121 shares of company stock worth $24,858,332. 4.10% of the stock is owned by corporate insiders.
Key Jazz Pharmaceuticals News
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
- Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
- Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing
Jazz Pharmaceuticals Stock Performance
NASDAQ JAZZ opened at $227.32 on Friday. The stock's fifty day moving average is $229.71 and its two-hundred day moving average is $217.40. The firm has a market capitalization of $14.59 billion, a P/E ratio of 20.80, a price-to-earnings-growth ratio of 0.47 and a beta of 0.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.58 and a current ratio of 1.82. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period in the prior year, the business posted $8.13 earnings per share. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on JAZZ shares. Deutsche Bank Aktiengesellschaft lifted their price objective on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a "buy" rating in a report on Wednesday, August 26th. Wells Fargo & Company increased their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an "overweight" rating in a report on Tuesday, August 4th. Barclays increased their target price on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an "overweight" rating in a report on Tuesday. Needham & Company LLC raised their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a "buy" rating in a research report on Wednesday, August 26th. Finally, TD Cowen lifted their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $293.45.
Check Out Our Latest Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Company Profile
(
Free Report)
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.